SA JOURNAL OF DIABETES & VASCULAR DISEASE
REVIEW
38. Realsen JM, Chase HP. Recent advances in the prevention of
hypoglycaemia in type 1 diabetes.
Diab Technol Ther
2011;
13
(12): 1177–1184.
39. Owens DR, Matfin G, Monnier L. Basal insulin analogues in
the management of diabetes mellitus: What progress have we
made?
Diabet Metab Res Rev
2013. doi: 10.1002/dmrr.2469.
Epub ahead of print.
40. Kerlan V, Gouet D, Marre M, Renard E. Use of insulin degludec,
a new basal insulin with an ultra-long duration of action, in
basal-bolus therapy in type 1 and type 2 diabetes.
Ann
Endocrinol
2013 Aug 23. pii: S0003-4266(13)00080-2. doi:
10.1016/j.ando.2013.04.004. [Epub ahead of print]
41. Freemantle N, Balkau B, Home D. A propensity score matched
comparison of different insulin regimens 1 year after beginning
insulin in people with type 2 diabetes.
Diabetes Obes
Metab
2013; Jun 19. doi: 10.1111/dom.12147. [Epub ahead
of print].
42. Gimenez M, Lara M, Conget I. Sustained efficacy of continuous
subcutaneous insulin infusion in type 1 diabetes subjects
with recurrent non-severe and severe hypoglycemia and
hypoglycemia unawareness: a pilot study.
Diabetes Technol
Ther
2010;
12
: 517–521.
43. Reznik Y, Cohen O. Insulin pump for type 2 diabetes: Use and
misuse of continuous subcutaneous insulin infusion in type 2
diabetes.
Diabetes Care
2013;
36
(Suppl 2): S19–S25.
44. Lv WS, Li L, Wen JP,
et al
. Comparison of a multiple
daily insulin injection regimen (glargine or detemir once daily
plus prandial insulin aspart) and continuous subcutaneous
insulin infusion (aspart) in short-term intensive insulin therapy
for poorly controlled type 2 diabetes patients.
Int J Endocrinol
2013; 2013:614242. doi: 10.1155/2013/614242. Epub 2013
May 8.
45. Amod A, Motala A, Levitt N,
et al.
The 2012 SEMDSA guideline
for the management of type 2 diabetes.
J Endocrin Medab
Diabetes S Afr
2012;
17
(1): S1–S94.
Lipanthyl + Statin Better Outcome
S3 LIPANTHYL
®
PJ (DFK FDSVXOH FRQWDLQV PJ IHQR¿EUDWH PLFURQLVHG 5HJ 1R
)RU IXOO SUHVFULELQJ LQIRUPDWLRQ UHIHU WR WKH SDFNDJH
LQVHUW DSSURYHG E\ WKH 0HGLFLQHV 5HJXODWRU\ $XWKRULW\ 'DWH RI 3XEOLFDWLRQ RI WKLV 3URPRWLRQDO 0DWHULDO -DQXDU\
$EERWW /DERUDWRULHV 6 $ 3W\ /LPLWHG
$EERWW 3ODFH *ROI &OXE 7HUUDFH &RQVWDQWLD .ORRI
7HO 1R
3URPR 1R =$(/,/
References: 1.
)DUQLHU 0 8SGDWH RQ WKH FOLQLFDO XWLOLW\ RI IHQR¿EUDWH LQ PL[HG GLVOLSLGHPLDV PHFKDQLVPV RI DFWLRQ DQG UDWLRQDO SUHVFULELQJ
Vasc Health Risk
Management
4
Scripting a
Statin
alone may have some
limitations - there could be something missing in
the management of mixed dyslipidaemia to reach
non-HDL-C goals.
Lipanthyl and Statins
work
better together as an ideal treatment that can
effectively reduce cardiovascular risk associated
with elevated triglyceride and low HDL-C levels.
1
Imagine if Jimi Hendrix had never
picked up a guitar. How would this
missing piece have affected our
history, our culture, our musical
heritage? Would rock have
disappeared in a purple haze?
Don’t leave out the piece that several guidelines
are recommending for correction of mixed
dyslipidaemia. Consider scripting Lipanthyl together
with a Statin for broader lipid management.
1
HDL-C = High density lipoprotein cholesterol
THE MISSING
PIECE IN LIPID
MANAGEMENT
